In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine
- 1 January 1982
- journal article
- research article
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 60 (1), 102-105
- https://doi.org/10.1139/y82-017
Abstract
Population data indicate that the genetic control is the same for the oxidation of sparteine and debrisoquine, although whether the level of control is regulatory or enzymatic is not clear. Therefore, the influence of debrisoquine on the rates of in vitro formation of the two dehydrogenated metabolites of sparteine in the 9000 × g supernatant fractions of human liver was examined. The interaction of these two drugs was competitive, indicating that the same form of cytochrome P450 is responsible for their biotransformation. Antipyrine at concentrations as high as 4 mM had no effect on sparteine oxidation.This publication has 4 references indexed in Scilit:
- Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in manLife Sciences, 1980
- Deficient metabolism of debrisoquine and sparteineClinical Pharmacology & Therapeutics, 1980
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977